IL111681A0 - Recombinant viruses and their use in gene therapy - Google Patents

Recombinant viruses and their use in gene therapy

Info

Publication number
IL111681A0
IL111681A0 IL11168194A IL11168194A IL111681A0 IL 111681 A0 IL111681 A0 IL 111681A0 IL 11168194 A IL11168194 A IL 11168194A IL 11168194 A IL11168194 A IL 11168194A IL 111681 A0 IL111681 A0 IL 111681A0
Authority
IL
Israel
Prior art keywords
gene therapy
recombinant viruses
viruses
recombinant
therapy
Prior art date
Application number
IL11168194A
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL111681A0 publication Critical patent/IL111681A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL11168194A 1993-11-18 1994-11-17 Recombinant viruses and their use in gene therapy IL111681A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9313772A FR2712603B1 (en) 1993-11-18 1993-11-18 Recombinant viruses, preparation and use in gene therapy.

Publications (1)

Publication Number Publication Date
IL111681A0 true IL111681A0 (en) 1995-01-24

Family

ID=9452977

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11168194A IL111681A0 (en) 1993-11-18 1994-11-17 Recombinant viruses and their use in gene therapy

Country Status (5)

Country Link
AU (1) AU8147294A (en)
FR (1) FR2712603B1 (en)
IL (1) IL111681A0 (en)
WO (1) WO1995014102A1 (en)
ZA (1) ZA949104B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
ATE211174T1 (en) * 1994-05-02 2002-01-15 Univ Washington THYMIDINE KINASE MUTANTS
DE69531387T2 (en) 1994-08-16 2004-04-22 Crucell Holland B.V. Recombinant vectors derived from adenovirus, for gene therapy
FR2725213B1 (en) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE IN GENE THERAPY
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
JP2002516061A (en) 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション Mutants of thymidine kinase and fusion proteins having thymidine kinase activity and guanylate kinase activity
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
ATE446368T1 (en) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic ANTIGENS FROM NEISSERIA MENINGITIDIS
DE69933856D1 (en) 1998-02-13 2006-12-14 Koester Hubert USE OF RIBOZYMES FOR DETERMINING THE FUNCTION OF GENES
EP2261355A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CN1074459C (en) * 1998-11-25 2001-11-07 马丁 Adenovirus-thymidine kinase gene configuration, and its acquiring process and application
DK1228217T3 (en) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Preserved Neisseria Antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CA2864069A1 (en) 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
ES2507100T3 (en) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. OMV vaccine supplemented against meningococcus
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
CN1405312A (en) * 2001-01-18 2003-03-26 中山卫健生物科技有限公司 Recombinant virus capable of specific killing tumor relating to EB virus and constructing method thereof
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
JP4413617B2 (en) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Immunization against CHLAMYDIATRACHOMATIS
US7741437B2 (en) 2002-09-19 2010-06-22 The United States Of America As Represented By The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
AU2003287267A1 (en) 2002-10-29 2004-05-25 Centro De Pesquisas Goncalo Moniz Lutzomyia longipalpis polypeptides and methods of use
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
CN101208104B (en) 2005-04-25 2012-10-31 梅瑞尔有限公司 Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
JP2009515529A (en) 2005-11-14 2009-04-16 メリアル リミテッド Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
PL2054431T3 (en) 2006-06-09 2012-07-31 Novartis Ag Conformers of bacterial adhesins
ES2760004T3 (en) 2008-05-08 2020-05-12 Boehringer Ingelheim Animal Health Usa Inc Leishmania vaccine using a salivary sand fly immunogen
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
CN103957932B (en) 2011-07-20 2017-06-23 梅里亚有限公司 Restructuring feline leukaemia virus vaccine comprising the feline leukaemia virus env gene for optimizing
EP3215188A1 (en) 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DE69114299T3 (en) * 1990-09-14 2005-09-15 The Johns Hopkins University METHOD AND COMPOSITIONS FOR GENERAL THERAPY AND STRENGTHENING OF THE IMMUNE SYSTEM.
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them

Also Published As

Publication number Publication date
WO1995014102A1 (en) 1995-05-26
FR2712603A1 (en) 1995-05-24
FR2712603B1 (en) 1996-02-09
ZA949104B (en) 1995-07-21
AU8147294A (en) 1995-06-06

Similar Documents

Publication Publication Date Title
IL111681A0 (en) Recombinant viruses and their use in gene therapy
IL115584A0 (en) Viral vectors and their use in gene therapy
ZA945012B (en) Viral vectors and their use in gene therapy
ZA951803B (en) Recombinant viruses their preparation and their therapeutic use
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
IL111682A0 (en) Recombinant viruses and their use in gene therapy
AU4032893A (en) Human papilloma virus genes and their use in gene therapy
SG54275A1 (en) Dna coding for decarbamylase improved in thermostability and use thereof
GB9214857D0 (en) Human nucleic acid fragments and their use
EP0623020A4 (en) Pyropheophorbides and their use in photodynamic therapy.
ZA945720B (en) Electrode and preparation thereof
IL105914A0 (en) Methods and compositions for in vivo gene therapy
EP0752472A4 (en) Novel gene originating in corynebacterium and use thereof
IL114982A0 (en) Use of a defective recombinant adenovirus in gene therapy
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
AU7665396A (en) Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
ZA952244B (en) Recombinant viruses their preparation and their use in gene therapy
GB2279956B (en) Recombinant human and rat AMP-protein kinases
ZA952286B (en) Recombinant viruses their preparation and their use in gene therapy
EP0692537A3 (en) Recombinant gibberellin DNA and uses thereof
ZA952243B (en) Recombinant viruses their preparation and their use in gene therapy
EP0690917A4 (en) Recombinant epstein-barr virus protein and its use in vaccine
GB9405875D0 (en) Recombinant molecules and their use in gene transfer
PH30808A (en) 2-Amino-4-heteroaryl-1,-4-2dihydropyridines and their use in medicaments.